This transcript has been edited for clarity.
Jay H. Shubrook, DO: Hi. I'm Jay Shubrook, a professor of primary care at Touro University California in the College of Osteopathic Medicine and a diabetologist. I'm happy to have with me today Anne Peters, a professor at the Keck School of Medicine and the director of the Westside Center for Diabetes at USC.
Today we're going to talk about the emerging evidence regarding the use of human insulins as maybe the standard for the treatment of type 2 diabetes. Dr Peters, we're glad to have you here today.
Anne L. Peters, MD: Good to be here with you, Jay.
Shubrook: A recent study published in JAMA about use of human and analogue insulins in the treatment of type 2 diabetes in the Medicare population.[1] So, tell me about this study.
Peters: It's a good question. The analogue insulins have become so expensive that many of our patients can't always afford them. The study basically looked at Medicare beneficiaries who had to switch and examined A1cs and reported rates of hypoglycemia.
We know it's hard to actually get reports of hypoglycemia. This is in part due to not coding every event, because you and I don't code every episode of hypoglycemia that happens.
